Attached files
| file | filename |
|---|---|
| EX-3.1 - FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Sierra Oncology, Inc. | d900346dex31.htm |
| EX-10.7 - FORM OF NICK GLOVER EMPLOYMENT AGREEMENT - Sierra Oncology, Inc. | d900346dex107.htm |
| EX-10.5 - FORM OF EXECUTIVE OFFICER EMPLOYMENT AGREEMENT - Sierra Oncology, Inc. | d900346dex105.htm |
| EX-1.1 - UNDERWRITING AGREEMENT - Sierra Oncology, Inc. | d900346dex11.htm |
| EX-4.1 - FORM OF COMMON STOCK CERTIFICATE - Sierra Oncology, Inc. | d900346dex41.htm |
| EX-10.3 - 2015 EQUITY INCENTIVE PLAN - Sierra Oncology, Inc. | d900346dex103.htm |
| EX-5.1 - OPINION OF FENWICK & WEST LLP - Sierra Oncology, Inc. | d900346dex51.htm |
| EX-10.4 - 2015 EMPLOYEE STOCK PURCHASE PLAN - Sierra Oncology, Inc. | d900346dex104.htm |
| S-1/A - S-1/A - Sierra Oncology, Inc. | d900346ds1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 1 to Registration Statement No. 333-204921 of our report dated April 8, 2015 (July 6, 2015 as to the effects of the reverse stock split described in Note 13) relating to the consolidated financial statements of ProNAi Therapeutics, Inc. (which report expresses an unqualified opinion and includes an explanatory paragraph referring to substantial doubt about the Company’s ability to continue as a going concern), appearing in the Prospectus, which is part of such Registration Statement.
We also consent to the reference to us under the heading “Experts” in such Prospectus.
/s/ Deloitte & Touche LLP
Detroit, Michigan
July 6, 2015